School of Medicine
Showing 4,341-4,360 of 12,925 Results
-
Zihuai He
Associate Professor (Research) of Neurology and Neurological Sciences (Neurology Research), of Medicine (BMIR) and, by courtesy, of Biomedical Data Science
Current Research and Scholarly InterestsStatistical genetics and other omics to study Alzheimer's disease and aging.
-
Rose Heald
Masters Student in Translational Research and Applied Medicine, admitted Autumn 2025
BioAs a Master’s student in Translational Research and Applied Medicine at Stanford Medicine, I’m passionate about bridging the gap between scientific discovery and real-world clinical impact. My career interests lie at the intersection of science and business, with a focus on advancing the development and implementation of novel therapeutics—particularly in the areas of genetics, rare disease, and neurodegenerative diseases.
I bring experience in clinical research, including work on the BabySeq Project, a pioneering study of genomic newborn screening (gNBS). This experience sparked my ongoing interest in how genomic technologies can be implemented to identify actionable health risks early in life. I continue to contribute to this field through my involvement with the International Consortium on Newborn Sequencing (ICoNS), a global initiative advancing gNBS research. -
Alesha Heath
Basic Life Research Scientist, Psych/Public Mental Health & Population Sciences
BioDr. Alesha Heath is a Postdoctoral Scholar at Psychiatry and Behavioral Sciences at Stanford School of Medicine and the MIRECC the VA Palo Alto. She earned her PhD from the University of Western Australia and Sorbonne University.
Dr. Heath's research has been primarily focused on the mechanisms and applications of brain stimulation therapies, in particular repetitive transcranial magnetic stimulation. Her research involves both basic and clinical components with the aim of improving the efficacy of these therapies for the treatment of disorders such as depression and Alzheimer's disease. -
Gregory M. Heestand, MD
Clinical Associate Professor, Medicine - Oncology
BioDr. Heestand is a board-certified medical oncologist with a focus on gastrointestinal cancers, primarily hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer. He serves as the medical oncology champion of the Stanford Hepatobiliary Tumor Board, as well as the principal investigator of multiple clinical trials. He collaborates with campus laboratories to help develop new biomarker and treatment technologies. He is the former director of the Stanford Oncology Fellowship Program.
Dr. Heestand and his team take great pride in helping patients and their families face gastrointestinal cancer.
Outside of the clinic, Dr. Heestand enjoys playing the piano, teaching his kids about music, cooking for friends and family, and surfing the internet for interesting things to read. -
Katherine (Heflin) Hefcart
Affiliate, Department Funds
Resident in Psychiatry and Behavioral SciencesBioAdult Psychiatry Resident, focusing on Community/Public Psychiatry, LGBTQ+ competent care, integrative mental health, and reproductive psychiatry. Attended Stanford undergraduate ('11), Harvard T.H. Chan School of Public Health ('15), Dartmouth Geisel Medical School ('23).
-
Nuriya Ruth Hefron
Professional - NX, Psych/Public Mental Health & Population Sciences
Current Role at StanfordProgram Manager INSPIRE 360
Expansion of Early Psychosis Care Program -
John P. Hegarty II
Clinical Assistant Professor, Psychiatry and Behavioral Sciences
BioI am a neuroscientist and Principal Investigator of the Stanford Clinical Neuroscience (CNS) Lab in the Department of Psychiatry and Behavioral Sciences as well as Director of Neuroimaging for the Autism and Developmental Disorders Research Program at Stanford. My innovative research studies clinical aspects of cognitive and behavioral neuroscience, with a special focus on examining the neural circuitry associated with important brain-behavior relationships that may underlie different psychological and psychiatric domains in autistic children, adolescents, and adults. The ultimate goal of this research is to improve our understanding of the development of different cognitive and behavioral skills in order to develop mechanistically driven interventions that will improve precision medicine for mental health. Biologically based diagnosis and treatment are extremely limited for most psychological and psychiatric conditions but also critically needed to increase early identification and improve treatment outcomes, especially for neurodevelopmental disorders in which early intervention is the most beneficial. My early career research has primarily focused on clinical neuroscience using neuroimaging (e.g., MRI & EEG) to examine the effects of different drugs and behavioral interventions on the brain, especially for developing biomarkers for improving treatment planning and monitoring biological changes in response to single dose and clinical trials.
My primary contributions to science thus far fall within these major categories: 1) identifying the neural correlates of individual differences in cognition and behavior, 2) developing new interventions and investigating the neurobiological substrates of response to treatment, 3) examining different factors that contribute to brain development, 4) summarizing and increasing accessibility to autism-related research, and 5) methods development for neuroimaging studies. My earliest research investigated the neurobiology of alexithymia, dyslexia, and stress using structural and functional magnetic resonance imaging to test theories of the mechanisms that contribute to differences in cognition and behavior. My subsequent dissertation research, in which I began to focus on neurodevelopmental disorders, examined the neural correlates of response to beta-blockers in autistic adults and also assessed the contribution of cerebellar circuits to the autism phenotype. During my postdoctoral training, I have developed further skills for working with children in multiple clinical research settings, especially for using advanced neuroimaging approaches to examine important brain-behavior relationships. This includes a recent K99/R00 from the National Institute of Child Health and Human Development (NCT04278898 & NCT05664789) that will assess the neurobiology of restricted and repetitive behaviors in autistic children and examine the efficacy and target engagement of a novel nutritional supplement and investigational drug, N-acetylcysteine (NAC), in the brain. You can find more information about our NAC studies at https://redcap.link/NACandAutism.
